PLOD3 expression is negatively correlated with different prognosis periods: e.g., breast cancer: overall, relapse free and distant metastasis free survival; or lung cancer: first progression, overall and postprogression survival (all p < 0.05, Supplementary Figure S6 also shows gastric, liver and ovarian cancer). Here, PLOD3 is linked to ovarian carcinoma.